| Literature DB >> 34062880 |
Emilio Fernández-Espejo1,2, Fernando Rodríguez de Fonseca3, Juan Suárez4, Eduardo Tolosa5,6,7, Dolores Vilas8, Iban Aldecoa9,10, Joan Berenguer11, Fátima Damas-Hermoso12.
Abstract
Background. Salivary α-synuclein (aSyn) and its nitrated form, or 3-nitrotyrosine-α-synuclein (3-NT-αSyn), hold promise as biomarkers for idiopathic Parkinson's disease (IPD). Nitrative stress that is characterized by an excess of 3-nitrotyrosine proteins (3-NT-proteins) has been proposed as a pathogenic mechanism in IPD. The objective is to study the pathological role of native αSyn, 3-NT-αSyn, and 3-NT-proteins in the saliva and submandibulary glands of patients with IPD. Methods. The salivary and serum αSyn and 3-NT-proteins concentration is evaluated with ELISA in patients and controls. Correlations of αSyn and 3-NT-proteins content with clinical features of the disease are examined. Immunohistochemical 3-NT-αSyn expression in submandibulary gland sections is analyzed. Results. (a) Salivary concentration and saliva/serum ratios of native αSyn and 3-NT-proteins are similar in patients and controls; (b) salivary αSyn and 3-NT-proteins do not correlate with any clinical feature; and (c) three patterns of 3-NT-αSyn-positive inclusions are observed on histological sections: rounded "Lewy-type" aggregates of 10-25 µm in diameter, coarse deposits with varied morphology, and spheroid inclusions or bodies of 3-5 µm in diameter. "Lewy-type" and coarse inclusions are observed in the interlobular connective tissue of the gland, and small-sized bodies are located within the cytoplasm of duct cells. "Lewy-type" inclusions are only observed in patients, and the remaining patterns of inclusions are observed in both the patients and controls. Conclusions. The patients' saliva presents a similar concentration of native αSyn and 3-nitrotyrosine-proteins than that of the controls, and no correlations with clinical features are found. These findings preclude the utility of native αSyn in the saliva as a biomarker, and they indicate the absence of nitrative stress in the saliva and serum of patients. As regards nitrated αSyn, "Lewy-type" inclusions expressing 3-NT-αSyn are observed in the patients, not the controls-a novel finding that suggests that a biopsy of the submandibulary gland, if proven safe, could be a useful technique for diagnosing IPD. Finally, to our knowledge, this is also the first description of 3-NT-αSyn-immunoreactive intracytoplasmic bodies in cells that are located outside the nervous system. These intracytoplasmic bodies are present in duct cells of submandibulary gland sections from all subjects regardless of their pathology, and they can represent an aging or involutional change. Further immunostaining studies with different antibodies and larger samples are needed to validate the data.Entities:
Keywords: lewy-type; nitration; nitrative stress; parkinson; saliva; α-synuclein
Year: 2021 PMID: 34062880 PMCID: PMC8147273 DOI: 10.3390/antiox10050715
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Demographic and clinical parameters, as well as concentration of salivary and serum αSyn and 3-nitrotyrosine proteins, in patients with IPD and control subjects.
| IPD (n = 45) | Control (n = 30) | P | |
|---|---|---|---|
|
| |||
| Age (years) | 61.4 ± 18.5 | 59.6 ± 11 | NS |
| Gender, male n (%) | 27(60) | 12 (40) | NS |
| Body mass index | 23.1 ± 2 | 24.8 ± 2.5 | NS |
| Education (years) | 17.8 ± 2.1 | 17.3 ± 2.2 | NS |
| Levodopa equivalent dose (mg per day) | 595.9 ± 650 | ||
| Disease duration (years) | 9.9 ± 6.8 | ||
| Age at IPD onset (years) | 57.9 ± 13.1 | ||
| Hoehn-Yahr stage | 2.1 ± 0.8 | ||
| Modified Schwab-England | 86 ± 25 | ||
| MDS-UPDRS part III (on) | 24 ± 12 | ||
| Total MDS-UPDRS (I-III) (on) | 37.2 ± 20 | ||
| MDS-UPDRS part IV | 1.2 ± 2.4 | ||
|
| |||
| Saliva | 361.9 ± 89 | 372.1 ± 91 | NS |
| Serum | 244,789 ± 114,017 | 297,783 ± 110,992 | NS |
| Saliva/serum αSyn ratio | 0.0015 ± 0.001 | 0.0013 ± 0.001 | NS |
|
| |||
| Saliva | 0.35 ± 0.28 | 0.33 ± 0.27 | NS |
| Serum | 1.52 ± 0.87 | 1.94 ± 1.23 | NS |
| Saliva/serum 3-NT-proteins ratio | 0.27 ± 0.25 | 0.21 ± 0.15 | NS |
Mean ± SD. Statistical comparisons were carried out with the χ2 test (dichotomous variables) or the Student’s t-test (quantitative variables). Abbrev.: IPD, idiopathic Parkinson’s disease; NS, nonsignificant; UPDRS, Unified Parkinson’s Disease Rating Scale; P, probability; αSyn, α-synuclein; 3-NT-proteins, 3-nitrotyrosine proteins.
Figure 1Individual total αSyn concentration (pg/mL) in (A) saliva and (B) serum in patients with IPD and control participants, as measured with ELISA. Mean and standard deviation are represented with solid lines. Abbrev.: αSyn, α-synuclein; IPD, idiopathic Parkinson’s disease; ELISA, enzyme-linked immunosorbent assay.
Correlation of native αSyn and 3-nitrotyrosine proteins concentration in the saliva with demographic and clinical parameters in patients with idiopathic Parkinson’s disease.
| Parameters | Native αSyn | 3-Nitrotyrosine Proteins |
|---|---|---|
| Age (years) | 0.192 | 0.027 |
| Body mass index | 0.215 | −0.058 |
| Education (years) | 0.071 | −0.065 |
| Levodopa equivalent dose (mg per day) | 0.166 | −0.209 |
| Disease duration (years) | 0.044 | −0.098 |
| Age at IPD onset (years) | −0.039 | 0.014 |
| Hoehn-Yahr stage | 0.179 | 0.006 |
| Modified Schwab-England | −0.102 | −0.161 |
| MDS-UPDRS part III (on) | 0.048 | −0.107 |
| Total MDS-UPDRS (I-III) (on) | 0.039 | −0.125 |
| MDS-UPDRS part IV | 0.206 | −0.198 |
Mean ± SD. Statistical correlation was carried out with the Pearson´s test. No significant correlations were found. Abbrev.: IPD, idiopathic Parkinson’s disease; αSyn, α-synuclein; NS, no significant; MDS-UPDRS, International Parkinson and Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale.
Figure 2Individual 3-NT-proteins concentration (µg/mL) in (A) saliva and (B) serum in patients with IPD and control participants, as measured with ELISA. Mean and standard deviation are represented with solid lines. Abbrev.: 3-NT-proteins, 3-nitrotyrosine proteins; IPD, idiopathic Parkinson’s disease; ELISA, enzyme-linked immunosorbent assay.
Figure 3Representative photomicrographs of submandibulary gland sections in patients with idiopathic Parkinson’s disease and controls, after immunostaining against 3-NT-αSyn (brown color) and IYD (grey color), or against 3-NT-αSyn alone (dark grey). (a–c) Rounded “Lewy-type” inclusions of 10–25 µm in diameter are observed in the interlobular connective tissue (white arrows). These inclusions are surrounded by a halo (a) or radiating fibrils (b,c). “Lewy-type” inclusions are observed in patients, not in controls. (d–i) 3-NT-αSyn-positive coarse inclusions are observed within the interlobular tissue, many of them close to duct cells (black arrows). Ribbon-like, spindle-like, and ovoid deposits are seen. (c,i–l) 3-NT-αSyn-immunoreactive spheroid bodies of 3–5 µm in diameter are observed in the cytoplasm of duct cells (yellow arrows). High-magnification images of intracytoplasmic bodies are seen in (j´,k´,l´). Bodies are observed in the patients and controls. (m) Low-magnification and double-stained image of a submandibulary gland section showing main cell types (1, interlobular connective tissue; 2, acini with IYD-negative cells; 3, ducts with IYD-positive cells; 4, adipocytes). Abbrev.: 3-NT-αSyn, 3-nitrotyrosine α-synuclein; IYD, iodotyrosine deiodinase; PD, Parkinson´s disease; CT, control gland. Bars: 10 µm in (a–l); 5 µm in (j´,k´,l´); 50 µm in m.
Demographic, clinical and neuropathological data from all cases studied with idiopathic PD and control participants.
| Demographic and Clinical Parameters | Patterns of Inclusions (Location) | |||||||
|---|---|---|---|---|---|---|---|---|
| Case | Gender | Age (y) | H-Y | Disease Duration (y) | “Lewy-Type” Inclusions (Interlobular Connective Tissue) | Coarse Aggregates | Small-Sized Bodies | Other Inclusions (Acinar Cells, Adipocytes, Endothelial or Blood Cells) |
| PD1 | F | 76 | 2 | 6 | 1 | 2 | 4 | 0 |
| PD2 | M | 73 | 2.5 | 8 | 2 | 2 | 3 | 0 |
| PD3 | M | 56 | 2 | 6 | 2 | 2 | 3 | 0 |
| PD4 | M | 55 | 2 | 7 | 2 | 2 | 4 | 0 |
| PD5 | M | 70 | 1.5 | 5 | 1 | 0 | 4 | 0 |
| PD6 | F | 71 | 2.5 | 7 | 2 | 1 | 3 | 0 |
| CT1 | M | 66 | 0 | 2 | 4 | 0 | ||
| CT2 | F | 55 | 0 | 2 | 3 | 0 | ||
| CT3 | F | 47 | 0 | 0 | 4 | 0 | ||
| CT4 | F | 66 | 0 | 2 | 4 | 0 | ||
| CT5 | M | 77 | 0 | 2 | 3 | 0 | ||
| CT6 | M | 60 | 0 | 0 | 3 | 0 | ||
The degree of immunoreactive inclusions within different regions of the submandibulary glands was assessed according to a five-point rating scale: not detectable (0), mild (1), moderate (2), frequent (3), and very frequent (4). Abbrev.: PD, Parkinson’s disease; CT, control; F, female; M, male; H-Y, Hoehn–Yahr stage.